Cellosaurus KMS-12-PE (CVCL_1333)

Cell line name KMS-12-PE
Synonyms KMS 12 PE; KMS-12PE; KMS12-PE; KMS12PE
Accession CVCL_1333
Resource Identification Initiative To cite this cell line use: KMS-12-PE (RRID:CVCL_1333)
Comments Part of: MD Anderson Cell Lines Project.
Doubling time: ~60-80 hours (DSMZ).
Omics: Deep RNAseq analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Pleural effusion.
Disease Plasma cell myeloma (NCIt: C3242)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_1334 ! KMS-12-BM
Sex of cell Female
Category Cancer cell line
STR profile Source(s): DSMZ; JCRB; PubMed=25877200

Markers:
AmelogeninX
CSF1PO9
D13S3178
D16S53911
D18S5115
D21S1130.2,32.2
D3S135816
D5S81814
D7S82011,12
D8S117916
FGA20
Penta D14
Penta E12,18
TH016,9
TPOX8,11
vWA14,16
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=2479409; DOI=10.1111/j.1365-2141.1989.tb00252.x
Ohtsuki T., Yawata Y., Wada H., Sugihara T., Mori M., Namba M.
Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32).
Br. J. Haematol. 73:199-204(1989)

PubMed=2519219
Ohtsuki T., Yawata Y., Namba M.
Establishment and characterization of five human myeloma cell lines.
Hum. Cell 2:297-303(1989)

PubMed=2768132; DOI=10.1007/BF02623725
Namba M., Ohtsuki T., Mori M., Togawa A., Wada H., Sugihara T., Yawata Y., Kimoto T.
Establishment of five human myeloma cell lines.
In Vitro Cell. Dev. Biol. 25:723-729(1989)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)

DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B
Otsuki T., Yamada O., Yata K., Nakazawa N., Taniwaki M., Sakaguchi H., Yawata Y., Ueki A.
Genetic and biological characterization of human myeloma cell lines: an overview of the lines established at Kawasaki Medical School.
Gene Funct. Dis. 1:48-56(2000)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

PubMed=11039672
Otsuki T., Hata H., Harada N., Matsuzaki H., Yata K., Wada H., Yawata Y., Ueki A., Yamada O.
Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient.
Int. J. Hematol. 72:216-222(2000)

PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2
Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S., Taniwaki M., Inazawa J.
Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.
Am. J. Pathol. 165:71-81(2004)

PubMed=16956823
Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L., Moreau P., Amiot M., Pellat-Deceunynck C.
The phenotype of normal, reactive and malignant plasma cells Identification of 'many and multiple myelomas' and of new targets for myeloma therapy.
Haematologica 91:1234-1240(2006)

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
Characterization of MYC translocations in multiple myeloma cell lines.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

PubMed=21173094; DOI=10.3324/haematol.2010.033456
Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D., Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M., Pellat-Deceunynck C.
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Haematologica 96:574-582(2011)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections DSMZ; ACC-606
IZSLER; BS TCL 239
JCRB; JCRB0430
Cell line databases/resources CGH-DB; 29-1
CGH-DB; 9140-4
LINCS_LDP; LCL-2044
Ontologies EFO; EFO_0006613
Biological sample resources BioSample; SAMN01821645
BioSample; SAMN01821692
BioSample; SAMN03472936
Chemistry resources ChEMBL-Cells; CHEMBL3308553
ChEMBL-Targets; CHEMBL2366257
Gene expression databases GEO; GSM99383
GEO; GSM827273
Polymorphism and mutation databases Cosmic; 753568
Cosmic; 2081426
Cosmic; 2367301